Probiotic Escherichia coli Nissle 1917 (EcN) for Successful Remission Maintenance of Ulcerative Colitis in Children and Adolescents: an Open-Label Pilot Study
The DOI matches its Crossref record.
Abstract
Since about 20 % of patients with ulcerative colitis (UC) are children and adolescents there is a need for therapeutic options custom-tailored to the children's needs. E. coli Nissle 1917 (EcN) as an evidence-based probiotic alternative to mesalazine (5-ASA) in adult UC remission maintenance is a promising agent for such a therapy. The present open-labelled pilot study was undertaken to investigate the clinical benefit of EcN for maintenance therapy in young UC patients. 34 patients with UC in remission aged between 11 and 18 years were allocated either to EcN (2 capsules o. d., n = 24) or 5-ASA (median 1.5 g/d, n = 10) and observed over one year. As a result, the relapse rate was 25 % (6 / 24) in the EcN group and 30 % (3 / 10) in the 5-ASA group. Data on the patients' global health and development were favourable and no serious adverse events were reported. In conclusion, maintenance therapy for UC with the probiotic EcN is effective also in young patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Dignass, A., Lindsay, J. O., Sturm, A., Windsor, A., Colombel, J.-F., Allez, M., D'Haens, G., D'Hoore, A., Mantzaris, G., Novacek, G., et al. (2012) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2012.09.002 · Cited by 1,548
Harbord, M., Eliakim, R., Bettenworth, D., Karmiris, K., Katsanos, K., Kopylov, U., Kucharzik, T., Molnár, T., Raine, T., Sebastian, S., et al. (2017) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjx009 · Cited by 1,180
Anti-Inflammatory and Immunomodulatory Effects of Probiotics in Gut Inflammation: A Door to the Body
Cristofori, F., Dargenio, V. N., Dargenio, C., Miniello, V. L., Barone, M., & Francavilla, R. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.578386 · Cited by 912
Encapsulation of probiotic living cells: From laboratory scale to industrial applications
Burgain, J., Gaiani, C., Linder, M., & Scher, J. (2011) · Journal of Food Engineering · doi:10.1016/j.jfoodeng.2010.12.031 · Cited by 887
Khan, I., Ullah, N., Zha, L., Bai, Y., Khan, A., Zhao, T., Che, T., & Zhang, C. (2019) · Pathogens · doi:10.3390/pathogens8030126 · Cited by 771
“The most commonly evaluated single probiotic strains that have been reported to be effective and as safe as mesalazine for the maintenance of remission in active UC patients are Lactobacillus GG [237,238], Escherichia coli Nissle 1917 [239,240], Bifidobacteria [241], and the yeast strain Saccharomyces boulardii [242].”
Background
Metadata
- Authors
- Henker, J., Müller, S., Laass, M., Schreiner, A., & Schulze, J.
- Venue
- Zeitschrift für Gastroenterologie
- Publisher
- Georg Thieme Verlag KG
- Published
- 2008-09-22
- Volume
- 46
- Issue
- 09
- Pages
- 874-875
- ISSN
- 0044-2771 (ISSN-L)
- 1439-7803
- OpenAlex
- W2083206326
- Cited by
- 128
- References
- 0
- FWCI
- 4.57
- Type
- journal article
- Language
- de
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Probiotic Escherichia coli Nissle 1917 (EcN) for Successful Remission Maintenance of Ulcerative Colitis in Children and Adolescents: an Open-Label Pilot Study. https://app.cochat.ai/papers/10.1055/s-2008-1027463
- The paper
- Henker, J., Müller, S., Laass, M., Schreiner, A., & Schulze, J. (2008). Probiotic Escherichia coli Nissle 1917 (EcN) for Successful Remission Maintenance of Ulcerative Colitis in Children and Adolescents: an Open-Label Pilot Study. Zeitschrift für Gastroenterologie. https://doi.org/10.1055/s-2008-1027463
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.